RenovoRx (NASDAQ:RNXT) Issues Quarterly Earnings Results

Key Points

• RenovoRx reported EPS of ($0.07), missing analyst expectations of ($0.06) by one cent. Revenue was $1.07 million, slightly above estimates of $1.06 million.
• Revenue reached a record, rising 17% sequentially and more than fourfold year over year; the company maintained its 2026 revenue guidance of $3.75 million to $4.25 million. Active commercial cancer centers grew from 21 to 26, with management targeting 36 by year-end.
• The company recorded a $3.6 million quarterly net loss and ended the quarter with $10.4 million in cash, which management expects to support operations into the second half of 2027. Enrollment in its Phase III TIGeR-PaC trial is complete, with initial results expected in the second half of 2027.

RenovoRx (NASDAQ:RNXT - Get Free Report) issued its earnings results on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.01), FiscalAI reports. The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $1.06 million. RenovoRx had a negative return on equity of 135.11% and a negative net margin of 621.71%.

Here are the key takeaways from RenovoRx's conference call:

• RenovoRx reported record third-quarter revenue of $1.07 million, up 17% sequentially and more than fourfold year over year, and maintained full-year 2026 revenue guidance of $3.75 million to $4.25 million.
• Active commercial cancer centers increased from 21 to 26, with more than 40 additional centers in the evaluation, approval, or activation pipeline. Management reiterated its year-end target of 36 active centers and cited repeat orders from most existing customers as a source of demand.
• Enrollment is complete in the Phase III TIGeR-PaC trial, with initial top-line results expected in the second half of 2027; the trial is evaluating targeted gemcitabine delivery against standard systemic therapy. Results are not yet available, and the timing leaves a substantial wait for a key clinical milestone.
• The company reported early expansion efforts beyond locally advanced pancreatic cancer, including a commercial sarcoma treatment and the first patient treated in a University of Vermont investigator-led trial of pre-surgical TAMP. These applications remain exploratory.
• RenovoRx posted a $3.6 million quarterly net loss, while SG&A rose to $2.9 million from $1.7 million a year earlier as it built commercial infrastructure. Cash was $10.4 million at quarter-end, which management said should fund operations into the second half of 2027; the balance included $3.5 million from warrant exercises.

RenovoRx Price Performance

RNXT stock traded down $0.12 during midday trading on Thursday, hitting $1.19. 344,808 shares of the company's stock were exchanged, compared to its average volume of 367,197. RenovoRx has a 1-year low of $0.70 and a 1-year high of $2.59. The business has a 50-day simple moving average of $1.55 and a two-hundred day simple moving average of $1.11.

Analyst Ratings Changes

RNXT has been the subject of a number of analyst reports. Wall Street Zen raised shares of RenovoRx from a "sell" rating to a "hold" rating in a report on Sunday. Weiss Ratings raised shares of RenovoRx from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

About RenovoRx

RenovoRx, Inc is a clinical-stage biopharmaceutical company developing targeted treatments for solid tumors. The company's approach is based on its Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver chemotherapy directly into tumor tissue through the arterial system while limiting exposure to surrounding healthy tissue.

RenovoRx's lead investigational product, RenovoCath, is a localized drug-delivery system intended to support the administration of anticancer therapies to tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.